Comprehensive Analysis of the Functions and Prognostic Significance of RNA-binding Proteins in Bladder Urothelial Carcinoma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2020 Dec 14

PMID 33312357

Citations 15

Authors

Changgang Guo

Ting Shao

Xiling Jiang

Dadong Wei

Zhanhua Wang

Mingyang Li

Guochang Bao

Affiliations

Soon will be listed here.

Abstract

Alterations in RNA-binding proteins (RBPs) are reported in various cancer types; however, the role of RBPs in bladder urothelial cancer (BLCA) remains unknown. This study aimed to systematically examine the function and prognostic significance of RBPs in bladder cancer using bioinformatics analyses. RNA sequencing and clinical data for BLCA were downloaded from The Cancer Genome Atlas (TCGA) database, and differentially expressed RBPs (DERBPs) between normal and cancer tissues were identified. A total of 388 DERBPs were identified, including 219 upregulated and 169 downregulated RBPs. All RBPs were screened for the prognostic model establishment and 9 RBPs (TRIM71, YTHDC1, DARS2, XPOT, ZNF106, FTO, IPO7, EFTUD2, and CTU1) were regarded as prognosis-related hub RBPs in BLCA. Further analysis revealed worse overall survival (OS) in the high-risk cohort compared to the model-based low-risk cohort. The area under the receiver operating characteristic (ROC) curve was 0.752 in the training group and 0.701 in the testing group, which supports the strength of its predictive ability. A nomogram was established according to nine prognosis-related RBPs, which showed strong predictive ability for BLCA. The C-indices of the nomogram were 0.7033 in the training group, and 0.6295 in the testing group. The prognosis-related hub RBPs may be involved in oncogenesis, development, and metastasis of BLCA. Our results will be of great significance in revealing the pathogenesis of BLCA, and developing new therapeutic targets and prognostic molecular markers for BLCA.

Citing Articles

Downregulated RBM5 Enhances CARM1 Expression and Activates the PRKACA/GSK3β Signaling Pathway through Alternative Splicing-Coupled Nonsense-Mediated Decay.

Zhang Y, Li F, Han Z, Teng Z, Jin C, Yuan H Cancers (Basel). 2024; 16(1).

PMID: 38201567 PMC: 10778212. DOI: 10.3390/cancers16010139.

DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma.

Liu X, Yuan L, Gao Y, Ming X, Zhang Y, Zhang Y J Transl Med. 2023; 21(1):574.

PMID: 37626419 PMC: 10463715. DOI: 10.1186/s12967-023-04454-3.

Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics.

Janin M, Davalos V, Esteller M Cancer Metastasis Rev. 2023; 42(4):1071-1112.

PMID: 37369946 PMC: 10713773. DOI: 10.1007/s10555-023-10120-3.

Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer.

Wu Q, Zheng S, Lin N, Xie X BMC Med Genomics. 2023; 16(1):87.

PMID: 37098532 PMC: 10127334. DOI: 10.1186/s12920-023-01521-y.

DARS2 is a prognostic biomarker and correlated with immune infiltrates and cuproptosis in lung adenocarcinoma.

Liu X, Zeng J, Zhang Y, Zhang Y, Gao Y, Liu C Am J Cancer Res. 2023; 13(3):818-834.

PMID: 37034224 PMC: 10077054.

References

Jonas K, Calin G, Pichler M . RNA-Binding Proteins as Important Regulators of Long Non-Coding RNAs in Cancer. Int J Mol Sci. 2020; 21(8). PMC: 7215867. DOI: 10.3390/ijms21082969. View

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Thul P, Akesson L, Wiking M, Mahdessian D, Geladaki A, Blal H . A subcellular map of the human proteome. Science. 2017; 356(6340). DOI: 10.1126/science.aal3321. View

Kilchert C, Strasser K, Kunetsky V, Anko M . From parts lists to functional significance-RNA-protein interactions in gene regulation. Wiley Interdiscip Rev RNA. 2019; 11(3):e1582. DOI: 10.1002/wrna.1582. View

Chatterji P, Rustgi A . RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer. Trends Mol Med. 2018; 24(5):490-506. PMC: 5927824. DOI: 10.1016/j.molmed.2018.03.008. View

Lin J, Hou Y, Huang S, Wang Z, Sun C, Wang Z . Exportin-T promotes tumor proliferation and invasion in hepatocellular carcinoma. Mol Carcinog. 2018; 58(2):293-304. PMC: 6587849. DOI: 10.1002/mc.22928. View

Nadal R, Bellmunt J . Management of metastatic bladder cancer. Cancer Treat Rev. 2019; 76:10-21. DOI: 10.1016/j.ctrv.2019.04.002. View

10.

Nechay M, Kleiner R . High-throughput approaches to profile RNA-protein interactions. Curr Opin Chem Biol. 2019; 54:37-44. PMC: 7131871. DOI: 10.1016/j.cbpa.2019.11.002. View

11.

Schuschel K, Helwig M, Huttelmaier S, Heckl D, Klusmann J, Hoell J . RNA-Binding Proteins in Acute Leukemias. Int J Mol Sci. 2020; 21(10). PMC: 7279408. DOI: 10.3390/ijms21103409. View

12.

Masuda K, Kuwano Y . Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers. Wiley Interdiscip Rev RNA. 2018; 10(3):e1520. DOI: 10.1002/wrna.1520. View

13.

Crabb S, Douglas J . The latest treatment options for bladder cancer. Br Med Bull. 2018; 128(1):85-95. DOI: 10.1093/bmb/ldy034. View

14.

Corley M, Burns M, Yeo G . How RNA-Binding Proteins Interact with RNA: Molecules and Mechanisms. Mol Cell. 2020; 78(1):9-29. PMC: 7202378. DOI: 10.1016/j.molcel.2020.03.011. View

15.

Garcia-Cardenas J, Guerrero S, Lopez-Cortes A, Armendariz-Castillo I, Guevara-Ramirez P, Perez-Villa A . Post-transcriptional Regulation of Colorectal Cancer: A Focus on RNA-Binding Proteins. Front Mol Biosci. 2019; 6:65. PMC: 6693420. DOI: 10.3389/fmolb.2019.00065. View

16.

Mohibi S, Chen X, Zhang J . Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer. Pharmacol Ther. 2019; 203:107390. PMC: 6848768. DOI: 10.1016/j.pharmthera.2019.07.001. View

17.

Beckmann B, Castello A, Medenbach J . The expanding universe of ribonucleoproteins: of novel RNA-binding proteins and unconventional interactions. Pflugers Arch. 2016; 468(6):1029-40. PMC: 4893068. DOI: 10.1007/s00424-016-1819-4. View

18.

Qin X, Li C, Guo T, Chen J, Wang H, Wang Y . Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway. J Exp Clin Cancer Res. 2017; 36(1):148. PMC: 5649064. DOI: 10.1186/s13046-017-0618-x. View

19.

Liu S, Huang M, Chen Z, Chen J, Chao Q, Yin X . FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020; 389(1):111894. DOI: 10.1016/j.yexcr.2020.111894. View

20.

Szczyrba J, Nolte E, Hart M, Doll C, Wach S, Taubert H . Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int J Cancer. 2012; 132(4):775-84. DOI: 10.1002/ijc.27731. View